<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316068</url>
  </required_header>
  <id_info>
    <org_study_id>sulodexide20110311</org_study_id>
    <nct_id>NCT01316068</nct_id>
  </id_info>
  <brief_title>Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients</brief_title>
  <acronym>Soften</acronym>
  <official_title>Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALFA WASSERMANN（BJ) Market Research and Management Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current therapies targeting albuminuria in diabetic nephropathy leave residual urinary
      albumin secretion, which meanwhile leave residual cardiovascular risk. Previous studies
      demonstrated that sulodexide could reduce albuminuria in type 2 diabetic patients. But no
      data concerning Chinese population is available. The investigators aim to provide evidence of
      effects of sulodexide on diabetic nephropathy in Chinese diabetic patients. Further the
      investigators also test the hypothesis that sequential administration of intravenous and oral
      replacement of the drug would gain an earlier and greater reduction of albuminuria, compared
      with oral use only.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in urine albumin/creatinine ratio</measure>
    <time_frame>52th week since the commence of therapy</time_frame>
    <description>conversion to normoalbuminuria and at least a 25% reduction in UACR opposed to baseline, or 50% reduction in UACR opposed to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in urine albumin/creatinine ratio and serum creatinine</measure>
    <time_frame>before and 2nd,12th,24th,36th and 60th week since the commence of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>sequencial use of sulodexide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral use of sulodexide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous use of sulodexide followed by oral use</intervention_name>
    <description>Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.</description>
    <arm_group_label>sequencial use of sulodexide</arm_group_label>
    <other_name>sequential use of sulodexide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>use of sulodexide orally only</intervention_name>
    <description>Patients receive 1000 LSU per day orally for 52 weeks</description>
    <arm_group_label>oral use of sulodexide</arm_group_label>
    <other_name>oral use of sulodexide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes based on WHO criteria

          -  Age 18-75 years old

          -  Serum creatinine ≤ 1.5 mg/dL (130umol/L)

          -  Albuminuria defined by a urine albumin/creatinine ratio(ACR) according to ADA criteria
             2009 (microalbuminuria by 30-299 ug albumin/mg creatinine and macroalbuminuria by ≥300
             ug albumin/mg creatinine on random spot urine collection )

          -  Continued stable seated systolic blood pressure &lt; 180 mmHg and diastolic blood
             pressure &lt; 110 mmHg

          -  Willing to change antihypertensive medication regimen if necessary

          -  Willing to provide written informed consent to participate in the study

          -  Willing to take contraception,or infertility for the duration of the study

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Present acute diabetic complication, or severe chronic diabetic complication(e.g.
             proliferative diabetic retinopathy)

          -  Complicating uncontrolled severe infection

          -  Hepatic insufficiency or renal insufficiency or severe disturbance of lipid metabolism

          -  Blood pressure ≥ 180/110mmHg

          -  Severe concomitant systemic disease(e.g. cardiac insufficiency, stroke), anticipated
             to be unable to finish the trial

          -  Uncooperative,unable to follow up, or anticipated unable to finish the trial

          -  Patients with other known specific renal diseases

          -  Untreated urinary tract infection that would impact urinary protein values

          -  Evidence of hepatic dysfunction including total bilirubin &gt; 2.0 mg/dL (34 mmol/L) or
             elevated transaminases

          -  History of Cardiovascular disease as follows: Unstable angina pectoris, myocardial
             infarction, transient ischemic attack, cerebrovascular accident, New York Heart
             Association Functional Class III or IV heart failure, obstructive valvular heart
             disease or hypertrophic cardiomyopathy

          -  Any risk of bleeding, or platelet count &lt; 100×109/L or anticipated surgery within
             research period

          -  Active, recurrent or metastatic cancer, or known HIV infection

          -  Participant in any experimental drug study in the past 90 days prior to the enrollment
             of the study, or plan to participate in any drug study during the study period

          -  Prior exposure to sulodexide, either in a clinical setting or as a participant in
             another clinical study

          -  Known allergy or intolerance to any heparin-like compounds or multiple drug allergies

          -  Lactation, pregnancy, or an anticipated or planned pregnancy during the study period

          -  Inability to give an informed consent or to cooperate with researchers (e.g.
             psychiatric disorder) or history of noncompliance to medical regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanbing Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>endocrinology department of the first affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Blouza S, Dakhli S, Abid H, Aissaoui M, Ardhaoui I, Ben Abdallah N, Ben Brahim S, Ben Ghorbel I, Ben Salem N, Beji S, Chamakhi S, Derbel A, Derouiche F, Djait F, Doghri T, Fourti Y, Gharbi F, Jellouli K, Jellazi N, Kamoun K, Khedher A, Letaief A, Limam R, Mekaouer A, Miledi R, Nagati K, Naouar M, Sellem S, Tarzi H, Turki S, Zidi B, Achour A; DAVET (Diabetic Albuminuria Vessel Tunisia Study Investigators). Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010 Jul-Aug;23(4):415-24.</citation>
    <PMID>20175052</PMID>
  </reference>
  <reference>
    <citation>Chen S, Fang Z, Zhu Z, Deng A, Liu J, Zhang C. Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats. J Huazhong Univ Sci Technolog Med Sci. 2009 Dec;29(6):715-9. doi: 10.1007/s11596-009-0608-0. Epub 2009 Dec 29.</citation>
    <PMID>20037813</PMID>
  </reference>
  <reference>
    <citation>Rossini M, Naito T, Yang H, Freeman M, Donnert E, Ma LJ, Dunn SR, Sharma K, Fogo AB. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant. 2010 Jun;25(6):1803-10. doi: 10.1093/ndt/gfp724. Epub 2010 Jan 7.</citation>
    <PMID>20061322</PMID>
  </reference>
  <reference>
    <citation>Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008 Feb;31 Suppl 2:S202-7. doi: 10.2337/dc08-s251. Review.</citation>
    <PMID>18227486</PMID>
  </reference>
  <reference>
    <citation>Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67(18):2681-96. Review.</citation>
    <PMID>18062718</PMID>
  </reference>
  <reference>
    <citation>Sulikowska B, Olejniczak H, Muszyńska M, Odrowaz-Sypniewska G, Gaddi A, Savini C, Cicero AF, Laghi L, Manitius J. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006;26(6):621-8. Epub 2006 Dec 21.</citation>
    <PMID>17191008</PMID>
  </reference>
  <reference>
    <citation>Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005 Sep-Oct;18(5):568-74.</citation>
    <PMID>16299683</PMID>
  </reference>
  <reference>
    <citation>Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlová M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicová J, Skrha J, Taton J, Grzeszczak W, Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002 Jun;13(6):1615-25.</citation>
    <PMID>12039991</PMID>
  </reference>
  <reference>
    <citation>Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract. 1997 Nov;38(2):109-14.</citation>
    <PMID>9483374</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>endocrinology department of the first affiliated hospital of Sun Yat-sen University</name_title>
    <organization>Yanbing Li</organization>
  </responsible_party>
  <keyword>diabetic nephropathy</keyword>
  <keyword>albuminuria</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>sulodexide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

